Ameriprise Financial Inc. Sells 645,170 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)

Ameriprise Financial Inc. cut its stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 97.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,326 shares of the company’s stock after selling 645,170 shares during the period. Ameriprise Financial Inc.’s holdings in Perspective Therapeutics were worth $55,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of CATX. Y Intercept Hong Kong Ltd bought a new stake in shares of Perspective Therapeutics during the fourth quarter valued at about $33,000. Aigen Investment Management LP purchased a new position in shares of Perspective Therapeutics during the fourth quarter worth about $34,000. National Bank of Canada FI grew its holdings in shares of Perspective Therapeutics by 549,900.0% during the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock worth $35,000 after purchasing an additional 10,998 shares in the last quarter. Vontobel Holding Ltd. purchased a new position in shares of Perspective Therapeutics during the fourth quarter worth about $51,000. Finally, Mercer Global Advisors Inc. ADV purchased a new position in shares of Perspective Therapeutics during the fourth quarter worth about $51,000. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Stock Up 6.4%

Shares of CATX stock opened at $3.32 on Friday. The stock has a fifty day moving average of $2.33 and a 200 day moving average of $2.87. Perspective Therapeutics, Inc. has a 52 week low of $1.60 and a 52 week high of $16.55.

Analyst Ratings Changes

Several brokerages have recently commented on CATX. Cantor Fitzgerald raised Perspective Therapeutics to a “strong-buy” rating in a report on Tuesday, March 4th. Wedbush reissued an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a report on Tuesday, May 13th. Royal Bank of Canada raised Perspective Therapeutics from an “outperform” rating to a “moderate buy” rating and boosted their price objective for the stock from $15.00 to $16.00 in a report on Tuesday, June 3rd. Scotiabank began coverage on Perspective Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price objective for the company. Finally, Truist Financial cut their target price on Perspective Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, May 14th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $12.63.

Insider Buying and Selling

In other Perspective Therapeutics news, CEO Johan M. Spoor purchased 22,026 shares of the company’s stock in a transaction that occurred on Friday, March 28th. The stock was bought at an average price of $2.24 per share, with a total value of $49,338.24. Following the completion of the purchase, the chief executive officer now directly owns 59,383 shares of the company’s stock, valued at $133,017.92. The trade was a 58.96% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Robert F. Williamson III acquired 22,192 shares of the firm’s stock in a transaction on Friday, March 28th. The stock was purchased at an average price of $2.27 per share, with a total value of $50,375.84. Following the acquisition, the director now owns 70,837 shares of the company’s stock, valued at $160,799.99. This represents a 45.62% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 115,696 shares of company stock valued at $256,344 over the last quarter. 3.72% of the stock is owned by company insiders.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.